Analysis of apheresis content of progenitor cell collections from normal donors to whom granulocyte‐colony‐stimulating factor is administered
Authors:
- J. J. NemunaitisJNJ. J. Nemunaitis
- S. AstonSAS. Aston
- M. J. MagsamenMMM. J. Magsamen
- C. S. RosenfeldCRC. S. Rosenfeld
- 12 November 1996
- journal article
- Published by Wiley in Transfusion
- Vol. 36 (11-12) , 943-947
Abstract
BACKGROUND: Allogeneic blood cell transplantation is a new alternative to bone marrow transplantation. Preliminary data suggest that granulocyte‐colony‐stimulating factor (G‐CSF)‐mobilized peripheral blood progenitor cells from normal donors can provide rapid hematopoietic engraftment without significant increases in transplant‐ related morbidity. Potential advantages to donors include the elimination of an operation under general anesthesia. STUDY DESIGN AND METHODS: Twenty‐one normal donors underwent high‐dose (16 pg/kg/day for 5 days) G‐CSF mobilization. Apheresis was performed on the fifth and sixth days of G‐CSF administration, and apheresis components were analyzed by flow cytometry. Donor characteristics in relationship to apheresis yields were also analyzed. RESULTS: Apheresis components were analyzed according to donor weight. The median total numbers of white cells per kg, CD34+ cells per kg, and CD3+ cells per kg were 10.8 × 10(6), 7.2 × 10(8), and 295 × 10(8), respectively. Day 5 collections had significantly higher nucleated cell content and median CD34+ percentages than did Day 6 collections (0.71% on Day 5 vs. 0.58% on Day 6, p < 0.01). CD34+ content and total white cells were not related to age or sex. No donors experienced toxic effects that required their removal from the study. CONCLUSION: Day 5 is the optimal day for the harvest of normal‐donor peripheral blood progenitor cells after mobilization with high‐dose G‐CSF. Older individuals are acceptable donors of allogeneic progenitor cells.Keywords
This publication has 8 references indexed in Scilit:
- Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.Journal of Clinical Oncology, 1996
- CD34: structure, biology, and clinical utility [see comments]Blood, 1996
- Optimizing dose and scheduling of filgrastim (granulocyte colony- stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers [see comments]Blood, 1995
- Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor [see comments]Blood, 1995
- Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) [see comments]Blood, 1995
- Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]Blood, 1995
- G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graftBritish Journal of Haematology, 1994
- Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapyBlood, 1993